Directors Gaby L. Longsworth, Ph.D. and Eric K. Steffe highlight the careful consideration one must make of obviousness-type double patenting, specifically with regard to potential patent term adjustment and patent term extension issues in the biotech and pharma industries. In light of recent rulings from the Federal Circuit, understanding this interplay proves paramount to patent drafting and prosecution.
To read the full article, please download the PDF.